Skip to Main Content

The 37-year drug development drought lives on.

Immunomedics (IMMU), the biotech founded in 1982, was informed by the Food and Drug Administration on Thursday night that its lead drug, an antibody drug conjugate to treat women with an aggressive form of breast cancer, could not be approved at this time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.